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Human Hp1-1 and Hp2-2 Phenotype-Specific Haptoglobin
Therapeutics Are Both Effective In Vitro and in Guinea Pigs
to Attenuate Hemoglobin Toxicity
Miriam Lipiski,1,* Jeremy W. Deuel,1,* Jin Hyen Baek,2 Wolfgang R. Engelsberger,1
Paul W. Buehler,2,{ and Dominik J. Schaer1,{
Abstract
Aims: Infusion of purified haptoglobin (Hp) functions as an effective hemoglobin (Hb) scavenging therapeutic in
animal models of hemolysis to prevent cardiovascular and renal injury. Epidemiologic studies demonstrate the
phenotype heterogeneity of human Hp proteins and suggest differing vascular protective potential imparted by
the dimeric Hp1-1 and the polymeric Hp2-2. Results: In vitro experiments and in vivo studies in guinea pigs were
performed to evaluate phenotype-specific differences in Hp therapeutics. We found no differences between the
two phenotypes in Hb binding and intravascular compartmentalization of Hb in vivo. Both Hp1-1 and Hp2-2
attenuate Hb-induced blood pressure response and renal iron deposition. These findings were consistent with
equal prevention of Hb endothelial translocation. The modulation of oxidative Hb reactions by the two Hp
phenotypes was not found to be different. Both phenotypes stabilize the ferryl (Fe4+) Hb transition state, provide
heme retention within the complex, and prevent Hb-driven low-density lipoprotein (LDL) peroxidation. Hb-
mediated peroxidation of LDL resulted in endothelial toxicity, which was equally blocked by the addition of
Hp1-1 and Hp2-2. Innovation and Conclusion: The present data do not provide support for the concept that
phenotype-specific Hp therapeutics offer differential efficacy in mitigating acute Hb toxicity. Antioxid. Redox
Signal. 19, 1619–1633.
Introduction
Hemoglobin (Hb) is released from red blood cells dur-ing multiple disease states, including hereditary hemo-
lytic anemias (e.g., sickle cell disease), malaria, and
extracorporeal circulation, as well as during massive blood
transfusion. In these conditions, extracellular Hb is both a dis-
ease marker and a toxin (11). Ligand binding of extracellular Hb
can alter nitric oxide (NO) and redox homeostasis, which can
lead to acute pulmonary and systemic hypertensive responses,
endothelial dysfunction, and oxidative tissue damage (38).
Moreover, the pathophysiology caused by acute and chronic
extracellular Hb exposure may contribute to tissue-specific se-
quelae associated with hemolytic conditions (38).
The physiologic detoxification systems for free heme and
Hb comprise a group of plasma scavenger proteins and their
respective cellular clearance receptors (38). In the case of Hb,
haptoglobin (Hp) binds Hb dimers in an irreversible large
protein complex, which is cleared by Hb:Hp scavenger re-
ceptors (1,11). In humans, this receptor has been identified as
the Hb scavenger receptor CD163, which enables endocytosis
of the complex by macrophages and peripheral blood
monocytes (20,37,39). Binding of Hb to Hp appears to fun-
damentally alter its potential to induce pathophysiology, as
the Hb:Hp complex protects against Hb toxicity by three
primary mechanisms (38): (i) Hp binds Hb dimers and se-
questers the Hb:Hp complex within the intravascular com-
partment, thereby limiting tissue exposure; (ii) Hp stabilizes
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the redox chemistry and the structure of bound Hb; and (iii)
Hp prevents release of hemewhen oxidized to its ferric (Fe3 + )
transition state. The potential therapeutic efficacy of Hp has
been suggested in preclinical models of hemolysis and
transfusion of significant quantities of stored blood, where
infusion of a plasma-derived Hp concentrate attenuates Hb-
driven vascular dysfunction, hemoglobinuria, and acute
kidney injury (4). Specifically, by providing intravascular se-
questration of Hb within the circulation, Hp prevented ac-
cumulation of free Hb in the kidneys of transfused animals.
Renal tubulus function and clearance capacity remained un-
changed in Hp-treated guinea pigs (4). The use of Hp as a
treatment modality is also supported by clinical experience
with a human plasma-derived Hp product approved for use
in Japan (38). Based on this evidence, several development
projects have recently commenced in the United States and
Europe, with the aim to explore the potential therapeutic
benefit of plasma-derived Hb scavenger proteins.
In humans, Hp has a genetic polymorphism that leads to
expression of three primary Hp phenotypes that share a
common Hb-binding b-chain, yet differ in their a-chain
composition (34,42). Hp phenotype 1-1 expresses a smaller
a-chain (a1), which can form only one disulfide bond to one
other a-b subunit. The resulting Hp is a dimeric (a1)2b2 Hp
molecule with a molecular weight of *85 kDa. In contrast,
Hp2-2 has a longer a chain (a2) that can form two disulfide
bonds with other Hp a-chains. The resulting Hp is a large
heterogeneous polymeric molecule composed of multiple
a and b subunits. Hp2-1 has a mixed a1 and a2 chain com-
position (21). Epidemiological studies have linked Hp2-2
genotype/phenotype carrier status to a higher risk of car-
diovascular complications in patients with diabetes
(13,21,22,26,33). Findings of these and similar studies sug-
gested that a ‘‘good’’ and a ‘‘bad’’ endogenous Hp pheno-
type may differentially impact vascular disease states with
underlying hemolytic components. However, it remains
unclear whether this evidence should imply that phenotype-
specific Hp therapeutics must be developed in order to exert
maximum therapeutic efficacy in hemolysis. During routine
Cohn fractionation of pooled human plasma, Hp1-1 and
Hp2-2 enrich in different fractions. Therefore, production
strategies to develop phenotype-specific Hp therapeutics at
large scale are feasible and currently employed by some
developers (15). For example, the Japanese Hp therapeutic
produced by Benesis contains only Hp2-2, while an inves-
tigational product developed by the British plasma frac-
tionation company Bio Products Laboratory (BPL) contains
predominantly Hp1-1.
The purpose of the present study is to understand the dif-
ferences between Hp1-1 and Hp2-2 interactions with Hb in a
series of in vitro and in vivo experiments and evaluate the
efficacy of the individual phenotype Hp preparations. The
thirdmajor phenotype, Hp2-1, was not examined in this study
because industrial isolation of this phenotype from pooled
plasma appears not to be less feasible. Data from this series of
experiments suggest that both Hp1-1 and Hp2-2 demonstrate
therapeutic efficacy in hemolytic conditions.
Results
Molecular characterization of two phenotype-specified
Hp therapeutics
Characterization of the composition and Hb binding of
two human plasma-derived and phenotype-specific Hp
therapeutics has been performed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and mass
spectrometry. SDS-PAGE indicates that both products are
predominantly composed of the respective Hp phenotype
(Fig. 1A). The phenotype specificity of the two products was
also confirmed by liquid chromatography–mass spectrometry
(LC-MS/MS) analysis (Supplementary Fig. S1). One of the Hp
products is approved as a therapeutic plasma protein in Japan
and comprises polymeric Hp phenotype 2-2 (characterized by
the larger a-2 chain in a reducing SDS-PAGE). The second
product is an Hp1-1-specified investigational therapeutic,
characterized by the smaller a-1 Hp chain. Impurities in the
two human plasma-derived products were identified by LC-
MS/MS and appear to be comparable (Fig. 1B). In both prep-
arations > 90% of the protein was identified as Hp. Subsequent
quantitativemass spectrometry analysis confirmed that the Hb
a/b chain contamination in both products is < 2%, relative to
the amount of Hp (data not shown). Total Hb binding capacity
(Fig. 1C and Supplementary Fig. S2) and Hb association (Fig.
1D) of the two Hp phenotype-specific products was deter-
mined by mass spectrometry and surface plasmon resonance
(SPR), respectively, and no significant differences were noted.
This data demonstrates that the Hp phenotype-specific thera-
peutics investigated in these studies do not demonstrate
quantitative differences in purity or Hb binding.
Attenuation of Hb-mediated hypertension is not Hp
phenotype dependent
One of the most extensively studied adverse effects of ex-
tracellular Hb is an acute hypertensive response (11). In earlier
studies, we have demonstrated that increased Hp expression,
Hb:Hp complex infusion, and supra-physiologic co-infusion
of Hp attenuates the hypertensive response induced by Hb
exposure in dog and guinea pig (4,9). In the present study we
explored whether Hp therapeutics attenuate hypertension in
guinea pigs when extracellular Hb is present in the circulation
and hypertension is established. Such a scenario has not yet
been studied, but ismore comparable to the actual therapeutic
Innovation
Haptoglobin (Hp) therapeutics are in the early stages of
development, when critical strategic approaches to pro-
duction process, proof-of-concept, nonclinical safety, and
early phase clinical study design define the future success
of novel pharmaceuticals. Hp is a multiphenotype plasma
protein suggested to have endogenous genotype-specific
vascular protective effects. Hp1-1 and 2-2 differences in
pathophysiologic outcomes are largely based on trans-
genic mouse models and epidemiological analyses that
find Hp1-1 to more effectively attenuate disease processes.
The present studies demonstrate that within the context of
treating acute hemolytic events, these two major pheno-
types of Hp (1-1 and 2-2) both display comparable efficacy
in vitro and in an established guinea pig model. These data
provide early proof of concept that is critical to Hp thera-
peutics development optimization.
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FIG. 1. Molecular characterization of phenotype-specified Hp therapeutics. (A) The phenotype-specified Hp preparations
that were used throughout these studies were analyzed by reducing (left) and nonreducing (right) SDS-PAGE electrophoresis.
Hp2-2 is comprised of a longer a2 chain and displays (in the nonreduced state) a heterogeneous multimeric state compared to
Hp1-1. (B) The major contaminants of plasma-derived Hp preparations have been determined by LC-MS/MS of trypsin-
digested Hp preparations. (C) Binding capacities of Hp phenotypes have been measured by quantitative mass spectrometry.
The input of the chromatography purified Hb:Hp complexes into the mTRAQ mass spectrometry analysis was quantified by
UV-VIS spectrophotometry ( = equal heme, left panel). The output provides relative quantification of Hp and Hb peptides in
the two complexes. The right panel displays ion current chromatograms of representative Hb (Hb727) and Hp (Hp560)
peptides, respectively. In these chromatograms, peptides derived from Hb:Hp1-1 (red) and Hb:Hp2-2 (blue) were discrim-
inated by their specific mass shift that was introduced by the mTRAQ labeling. For details of MS spectra see Supplementary
Figure S1. (D) Surface plasmon resonance recordings of Hb binding to Hp2-2 (left) and Hp1-1 (right) immobilized on a GLM
Proteon Sensor chip. Hp, haptoglobin; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; LC-MS/MS,
liquid chromatography–mass spectrometry; Hb, hemoglobin; mTRAQ, mass differential Tags for Relative and Absolute
Quantification; UV-VIS, UV-VIS spectrophotometry. To see this illustration in color, the reader is referred to the web version
of this article at www.liebertpub.com/ars
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situation where Hp may be administered. Both Hp pheno-
type-specific therapeutics significantly reduced blood pres-
sure compared to the (non-Hp-treated) control animals
when infused 10min after exposure to human oxy-Hb
(at a stable maximum blood pressure response) (Fig. 2A).
The mean – standard error (SE) maximum blood pressure
reduction was - 67.4% – 14.6% and - 76.1% – 9.1% following
Hp1-1 and Hp2-2 infusion, respectively (Fig. 2B). Hb infu-
sion alone maintained a stable blood pressure for *80min.
The mean area under the curve (AUC) – SE mean arterial
blood pressure (MAP) elevation from time 0 to 80min was
1360 – 84.9 in the Hb-only-treated animals. AUCs were sig-
nificantly lower following Hp1-1 (600 – 158) and Hp2-2
(532 – 228) infusion, respectively (Fig. 2C). These values did
not differ for Hp1-1 and Hp2-2 at Hb equivalent doses of
infused Hp protein. Supplementary Figure S3 shows sepa-
rate experiments where the two Hp products were infused
into control animals that were not pretreated with Hb. This
study confirms that Hp per se has no hypotensive effect. NO
consumption of purified Hb and the two Hb:Hp complexes
(Fig. 3A), as well as of plasma before and immediately after
Hp infusion, did not differ (Fig. 3B). These findings support
our previous assumption that the attenuation of free Hb-
mediated hypertension by Hp is not caused by changes in
global NO scavenging within the intra-vascular space.
Therefore, the (local) NO sparing effect is more likely due to
prevention of Hp-bound Hb from accessing the subendo-
thelial space, where NO consumption is most deleterious.
Hp1-1 and Hp2-2 restrict trans-endothelial Hb
redistribution
Previous studies suggest that the vascular protective effects
of Hp could be related to the ability of the large Hb:Hp
complexes to restrict passive diffusion and/or active trans-
port of free Hb across the endothelium into the subendothelial
space. This biological function of Hp may explain epidemio-
logical differences in vascular protection by (the smaller)
Hp1-1 and (the larger) Hp2-2 phenotypes. To test this
hypothesis, we investigated redistribution of Hb and pheno-
type-specificHb:Hp complexes across confluentmonolayers of
human umbilical vein endothelial cells (HUVECs) (Fig. 4). In
the absence of Hp, we observed significant redistribution of
Hb across the endothelium, with 53.5%– 3.6% of total Hb ap-
pearing in the abluminal compartment after 6h (Fig. 4A, B).
During the redistribution process Hb did undergo autoxida-
tion such that the final composition in both compartments was
*50% ferrous (Fe2+ ), 45% ferric (Fe3+ ), and 5% hemichrome.
However, Hb remained predominantly intact, as indicated by
size-exclusion chromatography (SEC) of the abluminal protein
demonstrating an identical chromatographic pattern to Hb
recovered from the luminal compartment (Fig. 4C). In addition,
FIG. 2. Equal efficacy of Hp phenotype-
specified therapeutics against Hb-induced
hypertension. (A) % change (D) in MAP
from baseline values to 180mg Hb is shown
as control (gray circles), Hp1-1 (open circles),
and Hp2-2 (dark circles) groups (n = 5/
group). In the Hp1-1 and Hp2-2 groups, each
Hp phenotype was administered in gram
equivalent dose 10min after the Hb infusion.
Animals were monitored continuously for
80min. (B) % change (D) maximum MAP
was determined as the change from maxi-
mum Hb-induced MAP response to MAP
after the Hp infusion (15min). (C) Area un-
der the MAP curve (AUC) was determined
by the linear trapezoidal rule for determining
AUC in the interval 0–80min using individ-
ual data plotted in (A). All data are repre-
sentative of mean values – SE. Statistical
significance was set at p < 0.05. Systolic and
diastolic blood pressures were measured
using a Gould pressure transducer with data
acquisition record using a BioPak data ac-
quisition system and AcqKnowledge soft-
ware for data analysis and MAP calculation.
MAP, mean arterial blood pressure; SE,
standard error.
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the quantity of free heme, as determined by a dialysis assay,
remained below detection limit in all conditions (data not
shown). This suggests that in this system all heme remains
bound to some protein and/or lipid components. When Hp
was present in the luminal medium, 97.6%– 0.3% of the Hp1-1
and 97.7%– 0.2% of the Hp2-2-bound Hb was sequestered,
significantly limiting transendothelial redistribution of both
Hb:Hp complexes. The end study composition of Hp-bound
Hb was *55% ferrous (Fe2+ ) and 45% ferric (Fe3+ ) with no
measurable hemichrome. The potential free Hb redistribution
mechanisms are passive diffusion or active transport of the
protein across the intact endothelial monolayer. An alternative
explanation for this phenomenon could be that free Hb or Hb
oxidation/degradation products damage the endothelium in
our experiments. In this case, the high concentration of ab-
luminal Hb would be a marker of endothelial damage and
subsequent ‘‘leakiness.’’ In an attempt to evaluate these sce-
narios, we have performed identical experiments as described
above in an electric cell impedance substrate measurement
(ECIS) instrument, as this enables measurement of transen-
dothelial electrical resistance in real time to determine mono-
layer integrity during Hb and Hb:Hp exposure. In these
experiments, we did not observe any changes in transen-
dothelial resistance with either free Hb or Hb:Hp complex in-
cubation (Fig. 4D). Accordingly, at the end of the experiments,
endothelial cells exposed to the different conditions displayed
equal adherence junction morphology (Fig. 4E). Further, nei-
ther Hb nor any of the Hb:Hp complexes impaired HUVEC
mitochondrial function as evidenced by unaltered cellular ATP
concentrations at the end of the 6-h incubation period (Fig. 4F).
We can thus conclude that redistribution of free Hb across the
endothelium is a significant pathophysiological component of
freeHb toxicity that is effectively prevented byHp therapeutics
of either phenotype.
Hp1-1 and Hp2-2 prevent free Hb redistribution
in guinea pigs
To validate the intravascular sequestration hypothesis in vivo,
we evaluated free and Hp-bound Hb plasma concentrations in
guinea pigs after infusion of Hb (60 and 180mg) alone and fol-
lowing treatment with the phenotype-specific Hp products
(Fig. 5). In the absence of Hp,Hb is rapidly cleared fromplasma.
This short circulation time is primarily the result of glomerular
filtration and Hb distribution to the kidneys. In contrast, fol-
lowingHp treatment, the complexedHb remained in circulation
over an extended period of time, consistent with previous
studies in this and several other species (9,30,31). In the present
study twomaximumplasma concentrations ofHb (expressed as
heme) were evaluated following intravenous infusion of 60mg
(Cmax=224–5.5lM plasma heme) and 180mg (Cmax=556–
60lM plasma heme) (Fig. 5A–D).Milligram equivalent doses of
Hp1-1 and Hp2-2 were infused 10min after Hb exposure. In the
60mg Hb group Hb:Hp was cleared from plasma by *30h
post-Hp administration. Pharmacokinetic parameters of Hb
(expressed as heme) bound to Hp1-1 and Hp2-2 were derived
from plasma concentration versus time curves (Fig. 5A, B).
Comparison of the primary exposure parameters (AUC0–30h and
plasma clearance) and the terminal half-life demonstrated no
difference between Hb bound to Hp1-1 or Hp2-2 (Fig. 5E–G).
The mean–SE for exposure parameters were as follows: AUC0–
30h 1526–72h$lg/ml (Hb:Hp1-1) and 1322–55h$lg/ml
(Hb:Hp2-2); plasma Cl, 157–8.0ml/h (Hb:Hp1-1) and
180–8.0ml/h (Hb:Hp2-2). The terminal half-life was 8.2–0.5h
for Hb:Hp1-1 and 8.4–2.3h for Hb:Hp2-2. The Cmax for Hb
alone was 220–12lM plasma heme, AUC0–4h was
231–30h$lg/ml, plasma Cl, 1004–127ml/h and the terminal
half-life was determined to be 1.0h. In the 180mg Hb exposure
group plasma concentrations of Hb:Hp leveled off at*200lM
heme. This observation suggests saturable kinetics within the
system and did not allow for meaningful pharmacokinetic
analysis. However, the long circulation time of the Hb:Hp
complex at the 180mg exposure may be considered reflective of
the intravascularHp sequestration ofHb. Similar to the previous
in vitro trans-endothelial redistribution findings, we did not
observe significant differences in the redistribution of Hb to the
kidneys following sequestration within Hp1-1 or Hp2-2 com-
plex. Renal iron deposition determined from the 180mg dosing
group was increased in Hb-infused animals (Fig. 6A); however,
FIG. 3. Hp1-1 and Hp2-2 do not change ex vivo NO con-
sumption by extracellular Hb. NO consumption of purified
Hb, Hb:Hp1-1, and Hb:Hp2-2 (A) or plasma samples from Hb
infused animals (B) has been measured with an NO-sensitive
electrode and serial 15ll (of 62.5lMHb/Hb:Hp complex solu-
tion) and 7.5ll (of plasma) injections, respectively, into a closed
equilibratedNO-producingsystem.Thedatarepresentmeansof
triplicate recordings (n= 3– SD), with three serial injections. In
(B), the three samples represent plasma collected after Hb infu-
sionat thetimeofpeakbloodpressureresponse(Hb,blacktrace)
and after therapeutic Hp application at the time of maximum
Hp-mediatedbloodpressureattenuation(Hp2-2,blue;orHp1-1,
red) (heme concentration= 542– 59lM [Hb alone group],
556– 27lM [Hp1-1 group], 550– 49lM [Hp2-2 group]). NO,
nitric oxide. To see this illustration in color, the reader is referred
to theweb version of this article at www.liebertpub.com/ars
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FIG. 4. Hp1-1 and Hp2-2 equally restrict trans-endothelial diffusion of extracellular Hb. Confluent HUVEC mono-
layers grown on a permeable trans-well cell culture insert were incubated on the ‘‘luminal’’ side with 300 lM Hb,
Hb:Hp1-1, or Hb:Hp2-2. After 6 h of incubation, total heme concentrations on the ‘‘luminal’’ (A) and ‘‘abluminal’’ (B) side
of the endothelial monolayer were quantified by UV-VIS spectrophotometry and by SEC (C), respectively. The results
indicate that the large molecular size of the Hb:Hp complexes fully restrict trans-endothelial diffusion of Hb. (D) The
integrity of the endothelial monolayer during Hb and Hb:Hp incubation was confirmed by identical experiments per-
formed in an ECIS instrument in order to measure trans-endothelial resistance over time. In absence or presence of Hp of
either phenotype, Hb treatment does not affect monolayer electrical resistance. (E) Adherence junction morphology was
examined on the ECIS electrodes at the end of the experiments shown in (D), where green indicates b-catenin, blue shows
4¢,6-diamidino-2-phenylindole stained nuclei. (F) Cellular ATP was quantified after 6 h of incubation under the same
condition as in the translocation assay with a luminescent assay. There was no significant difference among treatments.
Data are shown as mean – SE (n = 8). The negative control samples (negative) were complete assay reaction mix without
cells. HUVECs, human umbilical vein endothelial cells; SEC, size-exclusion chromatography; ECIS, electric cell im-
pedance substrate measurement. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
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both Hp phenotypes appeared to limit iron deposition. Percent
area analysis of kidney tissue stained positive for iron was
55.7%–8.6%, as measured 24h after Hb infusion. Following
Hp1-1 and Hp2-2 infusion, the percentage of areas staining
positive for iron were 6.93%–1.2% and 11.49%–0.9%, respec-
tively (Fig. 6B). These values were lower than those corre-
sponding to Hb alone. However, they were not different from
each other, suggesting that both Hp1-1 and 2-2 prevent renal
iron deposition. To quantitatively compare the intravascular Hb
sequestration by the two Hp products in vivo, we have quanti-
fied complex formation and Hb binding in post-infusion
plasmas of Hp-treated guinea pigs over a range of Hb concen-
trations. These data are shown in Figure 6C and in Supple-
mentary Figure S4. Also in these studies, we did not detect a
significant difference in the total Hb binding capacities of the
two Hp phenotypes in vivo.
Ferryl Hb stabilization, heme release, and attenuation
of oxidative toxicity are not related to Hp phenotypes
Stabilization of the Hb structure and its redox chemistry
have been considered essential components of Hp protection
FIG. 5. Extravascular decompartmentalization of Hb, Hp1-1, and Hp2-2. Plasma concentration versus time curves of
plasma Hb (expressed as heme concentration). (A) Hemoglobin infusion (60mg) followed by Hp1-1 (60mg) infused at 10min
post-Hb infusion. (B) Hemoglobin infusion (60mg) followed by Hp2-2 (60mg) infused at 10min post-Hb infusion. (C) He-
moglobin infusion (180mg) followed by Hp1-1 (180mg) infused at 10min post-Hb infusion. (D) Hemoglobin infusion (180mg)
followed by Hp2-2 (180mg) infused at 10min post-Hb infusion. In both panels, black and white open circles and dark squares
represent bound and free Hb, respectively, whereas open circles represent the plasma concentration–time curve of Hb alone.
Comparison of primary pharmacokinetic data from the 60mg Hb exposure group (E) AUC0–4h Hb, AUC0–30h Hb:Hp1-1 and
Hb:Hp2-2. (F) Plasma clearance (dose/AUC) based on Hb AUC0–4h, and Hb:Hp AUC0–30h. (G) Terminal elimination half-life
based on the negative value of the terminal slope (k) of the log-linear plasma concentration–time curve for Hb, Hb:Hp1-1, and
Hb:Hp2-2. Parameters were all significantly different ( p< 0.001) between Hb and Hb:Hp complexes, but not between Hb:Hp1-1
and Hb:Hp2-2 based on a nonparametric analyses (Kruskal–Wallis test followed by a Dunns post-test for group comparisons).
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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against Hb toxicity (8,10,14,32,41). In the present study, Hb
oxidation/reduction reactions were monitored by UV-VIS
spectrometry in a system with glucose oxidase (GOX) as a
source of continuous low-level hydrogen peroxide (H2O2).
The different reaction products were calculated from the
raw data by spectral deconvolution (Fig. 7). In the absence
and in the presence of Hp, we observed a comparable rapid
transition of oxy-Hb(Fe2 + ) to ferryl-Hb(Fe4 + ), although, in
the presence of Hp, the decay of Hb(Fe4 + ) was slower than
in the absence of Hp (Fig. 7A). The modeled ferryl kinetics
revealed slower decay rates k2 (min
-1) for Hb:Hp than for free
Hb over a range of glucose oxidase (GOX) concentrations. The
rates for Hb:Hp1-1 andHb:Hp2-2 were not statistically different
(Fig. 7B). A structurally nondefined porphyrin degradation
product appeared delayed when Hp of either phenotype was
present in the reaction. To further confirm the stability of ferryl-
Hb(Fe4+ ) in the Hb:Hp complex, we performed additional ex-
periments inwhich an excess of catalasewas added—in order to
terminate Hb(Fe3+ ) to Hb(Fe4+ ) transition—at a time when all
Hb was oxidized to Hb(Fe4+ ) (*12min after the reaction
commenced) and followed the decay of Hb(Fe4+ ) over time
(Fig. 7C). Compared to Hb alone, the stability of Hb(Fe4+ ) was
markedly enhanced in the presence of Hp1-1 and 2-2. Again, no
apparent differences between the two Hp phenotypes were
observed.
Heme release from ferric (Fe3 + ) Hb was measured over
time in an Hb-hemopexin (Hpx) heme transfer assay (Fig. 8).
In a reaction mixture containing ferric (Fe3 + ) Hb and Hpx, we
noted a gradual disappearance of the characteristic HbFe3 +
UV-VIS spectrum (red trace) and an increase of the spectrum
that is specific for the heme-Hpx complex (blue trace) (Fig.
8A). This spectral transition reflects the transfer of heme from
Hb to Hpx. The concentrations over time of met-Hb and
heme-Hpx were calculated by spectral deconvolution and the
decay rate of met-Hb calculated by fitting the data to a double
exponential model, which might be reflective of the different
heme release kinetics of Hb a- and b- chains, respectively (18)
(Fig. 8B and Table 1). Compared to free Hb, there was no
significant heme transfer detected with the Hb:Hp complexes
of either phenotype (Fig. 8C, D). One potential mechanism of
Hb toxicity is related to the transfer of heme from HbFe3 + to
lipoproteins, particularly low-density lipoprotein (LDL), with
subsequent oxidation of the LDL. We measured LDL oxida-
tion by HbFe3 + and the HbFe3 + :Hp complexes, respectively,
and found that Hp of both phenotypes prevented LDL oxi-
dation equivalently (Fig. 8E). In vivo, endothelial damage by
heme-oxidized LDL is a critical toxicity associated with Hb
following hemolysis.We have therefore established an in vitro
model of endothelial toxicity that is driven by in situ oxidation
of LDL. As shown in Figure 8F, Hp of both phenotypes sig-
nificantly delays the breakdown of endothelial barrier function
that occurs when the endothelium is exposed to LDL andHb in
the presence of low (nontoxic, 5–10lM) H2O2 concentrations.
Discussion
Epidemiological gene association studies suggest that ex-
pression of the Hp2-2 genotype might be a risk factor for
morbidity and mortality in a variety of vascular diseases as-
sociated with local or systemic hemolysis (13,21). The mech-
anisms that support this hypothesis are based on the
observations of decreased clearance of Hp2-2-bound Hb and
FIG. 6. Equal prevention of renal iron deposition by Hp1-
1 and Hp2-2. (A) Representative Perls iron stained kidney
tissue with 3,3¢-diaminobenzidine intensification showing
nontreated (upper left), Hb (upper right), Hb+Hp1-1 (lower
left), and Hb +Hp2-2 (lower right). (B) Image analysis was
performed using ImageJ to determine the ratio of iron-
stained area to the total area of 20 images (10· ) of n = 5
individual animals. Percentage areas are represented as
mean – SE. (C) Ex vivo Hb binding of guinea pig plasmas was
measured by SEC after infusion with either Hp1-1 or Hp2-2.
The figure shows chromatogram areas (AU*min) of Hb-
bound Hp components (=Hb:Hp complex) plotted against Hb
concentration. Details are provided in Supplementary Figure
S4. To see this illustration in color, the reader is referred to the
web version of this article at www.liebertpub.com/ars
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increased potential for oxidative stress mediated by heme and
iron release (2,3,26,33). Human plasma-derived Hp is ap-
proved and marketed in Japan for a wide range of hemolytic
conditions (38). Recently, certain U.S. and European plasma
fractionators have initiated development programs to isolate
Hb-binding proteins and are currently evaluating potential
disease-state indications (15). Given these important devel-
opments in this field and the extensive knowledge of a po-
tential Hp phenotype-specific predictor of poor disease
outcome, the experiments described here were designed to
detect differences in Hp1-1 and Hp2-2 interactions with Hb
when considered as a therapeutic agent. The experimental
results were able to address the relevance of phenotype forHp
therapeutics in acute hemolytic conditions and serve as a
proof of concept for future drug development initiatives.
Our studies demonstrate that the protein composition of
the evaluated commercial Hp products are predominantly
dimeric (Hp1-1) andmultimeric (Hp2-2), respectively. Protein
impurity content was found to be nearly identical in both
preparations, based on quantitative mass spectrometry. Cer-
tain studies suggest that the overall binding capacity of Hp1-1
is greater than that of Hp2-2 (3,23), supporting the concept
that Hp2-2 may be a less effective Hb binding protein in vivo.
In the present study, SPR analysis demonstrated similar Hb
association kinetics for each phenotype, whereas quantitative
mass spectrometry analysis found no differences in the
binding capacity for Hb within Hp1-1 and Hp2-2. These
findings suggest that in vivo sequestration of Hb should be
similar for the two phenotypes. This concept is supported by
data presented in Figure 2, where infusion of Hb, followed by
either Hp1-1 or Hp2-2, demonstrated similar blood pressure
attenuating capability. Additionally, curves depicted in Fig-
ure 5 show similar temporal changes in plasma heme con-
centration for bothHp1-1- andHp2-2-bound and freeHb. This
data correlated with renal iron deposition, suggesting that the
Hb was effectively compartmentalized within the vascular
space by both Hp phenotypes. The present data was derived
from dosing on a milligram Hb to milligram Hp basis. How-
ever, it is critical to note that clinical dosing will likely differ
significantly. Given the dynamic range of Hb concentrations
that can occur, relevant dosing approaches in complex clinical
conditions may require titration and or dose escalation within
the range allowed by defined safety margins.
Although definitive mechanism for the MAP attenuating
effects of Hp remains difficult to resolve, it has been suggested
that Hp can prevent Hb extravasation from the circulation
into the peri-vascular space (4,19,28). Data presented in Figure
3 demonstrate that blood/plasma sampled after Hb infusion
consumes NO ex vivo to the same extent as blood/plasma
sampled after Hp infusion (when Hb was predominantly Hp
FIG. 7. Hb:Hp1-1 and Hb:Hp2-2 stabilize the Hb ferryl state. (A) Hb-Fe2 + (12.5 lM) or the respective Hp complexes were
incubated with 40mU of glucose-oxidase (in phosphate buffered saline 20mM) as a source of continuous hydrogen peroxide
at 37C. The absorbance over the wavelength range of 300–700 nm was measured during 5 h. The amounts of different Hb
reaction products were extracted by spectral deconvolution. While Hp1-1 and Hp2-2 complexes of Hb indicate identical
reaction patterns over time, free Hb shows a more rapid decline of ferryl (Fe4 + ) concentrations (red line) with a concurrent,
more rapid increase of a structurally nondefined porphyrin degradation product (black line). (B) Ferryl decay rates (k2) over a
range of GOX concentrations. Experimental design and readout as shown in (A). Red: free Hb; blue: Hb:Hp1-1; gray:
Hb:Hp2-2. The plotted line represents a linear regression– 95% confidence interval. N= 3 experiments. (C) Identical experi-
ments were repeated with 200 nM of bovine catalase added after the first 12min. The recordings demonstrate that, in the
presence of both Hp phenotypes, the ferryl (Fe4+ ) state of Hb is much more stabile compared to free Hb. GOX, glucose oxidase.
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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bound). This is consistent with previously published data
using the same assay to confirmNOconsumption in hemolysing
sickle cell patient blood/plasma (35) and in previous studies
showing equivalent NO consumption with the Hb:Hp complex
(4). Collectively, these studies establish no differential NO
binding between Hb and the Hb:Hp complex of either pheno-
type. Data shown in Figure 4 suggest that Hb transport across
the vascular endotheliumcould be equally inhibitedover timeby
the addition ofHp1-1 andHp2-2. Almost 100%ofHp-boundHb
was prevented from crossing cultured endothelial monolayers,
while Hbwas able to extravasate to amaximumof 45% over a 6-
h period. Hb translocation was not associated with endothelial
resistance changes or significant adherence junction disruption,
potentially indicating that an active transport mechanism for Hb
perivascular translocation exists. This transport mechanismmay
be not accessible for Hb:Hp complexes, either due to its large
molecular size or altered surface charge state.
FIG. 8. Hp1-1 and Hp2-2 restrict
heme release and protect against LDL
peroxidation-driven endothelial
damage. (A–D) Heme release from
free met-Hb (Fe3 + ) or from the re-
spective complexes with Hp1-1 and
Hp2-2 was probed using an Hb-Hpx
heme transfer assay. Serial UV-VIS
spectra were recorded over time (15 h
at 37C) with reaction mixtures con-
taining 12.5 lM HbFe3 + (A), HbFe3 + :
Hp1-1 (C), and HbFe3 + :Hp2-2 (D) and
an excess of Hpx. The first spectrum
(t0) is highlighted in red and the last
spectrum (t15h) in blue. The relative
quantities of met-Hb (solid lines) and
heme-Hpx (dashed lines) were calcu-
lated by spectral deconvolution. (E)
Hb-driven LDL peroxidation. About
5lM heme equivalent of free Hb,
Hb:Hp1-1, or Hb:Hp2-2 was injected
into a 0.1mg/ml LDL solution in a
closed system. Oxygen was monitored
as a surrogate parameter of LDL per-
oxidation in the system using an oxy-
gen sensor. Data are represented as
mean– SE of triplicate experiments. (F)
LDL peroxidation-driven endothelial
damage. Confluent monolayers of
HUVECs were grown in an ECIS in-
strument and treated with 0.1mg/ml
LDL and 2.5mU GOX as a source of
continuous low-level hydrogen perox-
ide exposure. In the absence of Hb, no
change in electrical resistance was ob-
served. Endothelial integrity was rap-
idly damaged when free Hb was
added to the reaction (decrease of en-
dothelial resistance). This endothelial
damage was attenuated/delayed in
the presence of either Hp1-1 or Hp2-2.
LDL, low-density lipoprotein; Hpx,
hemopexin. To see this illustration
in color, the reader is referred to the
web version of this article at www
.liebertpub.com/ars
Table 1. Rates of met-Hemoglobin Decay Resulting
from Heme Transfer to Hemopexin
k1 (s
- 1) k2 (s
- 1) R2
met–Hb 3.51 0.60 5.35
met-Hb:Hp1-1 0.05 - 0.03 3.51
met-Hb:Hp2-2 0.07 - 0.03 14.79
Data for met-Hb concentrations· time were fitted to the following
model
[Hb]¼ [Hb]0
2
 (e k1tþ e k2 t):
Hb, hemoglobin; Hp, haptoglobin.
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The capacity for clearance of theHb:Hp complex appears to
differ among mammalian species. Studies in mice, guinea
pigs, and dogs suggest a slow circulatory clearance of
Hb:Hp complex that becomes saturated, particularly at supra-
physiological Hb:Hp concentrations (4,9). Inmice, this may be
associated with lower Hb:Hp binding affinity to CD163 (17).
In humans, no specific studies have been performed to ad-
dress supra-physiologic circulatory exposure to Hb:Hp. The
pharmacokinetic capacity of humans to effectively clear
Hb:Hp by the CD163-monocyte/macrophage system remains
a critical unanswered question. However, within the physio-
logical range of Hp levels, Hb appears to be effectively cleared
from human circulation (29). The capacity of specific clearance
of human Hb:Hp by the guinea pig macrophage system is not
known. Therefore, the comparable rates of delayed complex
disappearance of Hb:Hp1-1 and Hb:Hp2-2 in our studies
should be primarily interpreted as indicative of the equal
capacity of the two phenotypes to sequester Hb within the
circulation (e.g., prevention of renal filtration and prevention
of trans-endothelial translocation of Hb into the extravascular
space). Earlier in vitro studies have suggested that Hb:Hp1-1
might be cleared faster by human CD163 than Hb:Hp2-2.
However, when examined in our previously reported endo-
cytosis model, which is based on a human CD163-transduced
HEK-293 cell line (12,36,39), we found a slightly increased
complex uptake and enhanced heme-oxygenase (HO-1) ex-
pression with Hb:Hp2-2 (Supplementary Fig. S5). These
findings appear to be better compatible with the higher af-
finity of Hb:Hp2-2 that was reported in the initial description
of the Hb scavenger receptor (20). Collectively, these con-
flicting results together with the known species differences in
the Hb scavenger system underpin the limitation of studies
focusing on receptor-mediated Hb clearance in cell-based
assays and in experimental animal models. Therefore, sepa-
rate studies in human could most effectively address the po-
tential for phenotype-dependent Hb:Hp clearance during
early clinical trials.
The antioxidant function of Hp has previously been sug-
gested to attenuate the following sequence: heme iron oxi-
dation to the Hb(Fe4 + ) transition state, peroxide-driven redox
cycling of Hb(Fe4 + ) to Hb(Fe3 + ), free radical generation and
heme release, radical and/or heme transfer to LDL, and ac-
cumulation of oxidized LDL (oxLDL) (24,25). Free heme and
oxLDL are potential mediators of tissue injury and under-
standing the contribution of Hp1-1 and Hp2-2 phenotypes to
slowing down the generation of these intermediates may
provide insight into the potential therapeutic benefits specific
to either Hp1-1 or Hp2-2 (5–7,27). In vitro data presented here
suggest that Hb redox cycles between Hb(Fe4 + ) andHb(Fe3 + )
in vitro and that both Hp phenotypes stabilize the Hb(Fe4 + )
transition. Moreover, the two phenotypes prevent heme re-
lease from Hb and subsequent peroxidation of LDL. Func-
tionally, these observations appear to be associated with
protection against endothelial damage that is mediated by
Hb-driven LDL peroxidation.
Collectively, our findings suggest that Hp1-1 and Hp2-2
would likely provide equivalent therapeutic efficacy in the
treatment of acute hemolysis. Equal Hb protection by the two
Hp phenotypes is also suggested by the recently resolved
structure of the Hb:Hp complex, which confirmed that Hb
binding is exclusively provided by the conserved Hb b-chain,
without any involvement of the heterogeneous a-chain (1).
Our findings remain a separate physiologic concept from
known epidemiologic differences in disease susceptibility to
Hp genotype. However, it is likely that disease associations
may not be explained by differences in the primary Hb de-
toxification functions of Hp phenotypes, but by other prop-
erties of the molecule. The different molecular conformations
of Hp phenotypes may affect post-translational processing
and secretion, which may lead to altered plasma and/or tis-
sue concentrations of endogenous Hp. Lower total plasma
concentrations and correlated Hb binding capacities have
indeed been described in some populations with the Hp2-2
phenotype (16,43). Alternatively, other functions of Hp
such as its immune-modulatory effects might be phenotype
dependent (40).
In conclusion, our studies support Hp’s in vitro and in vivo
therapeutic efficacy against Hb toxicity for a wide range of
biochemical and physiological processes. Due to inherent
experimental and statistical limitations, proving equal activity
of two compounds is difficult, and we cannot exclude that
some minor difference do exists in the Hb protective activity
of Hp1-1 and Hp2-2, or eventually of the third phenotype,
Hp2-1, which was not examined in these studies. However, it
remains unlikely that such minor differences will measurably
affect the Hb protective therapeutic efficacy of an Hp product.
The presented data represent an initial proof of concept that
both Hp1-1 and Hp2-2 protect against Hb-driven toxicity.
These observations may help therapeutic development deci-
sions to increase production yield anddecrease production cost
of Hp therapeutics while maintaining therapeutic efficacy.
Materials and Methods
Haptoglobin therapeutics and Hb
Human Hb was purified to remove catalase by ion ex-
change chromatography on a DEAE Sephadex column (GE-
Healthcare). Hb endotoxin levels were < 0.05 endotoxin
units/ml (Pyrogent Plus; Lonza). A Hp1-1 phenotype-
specified investigational therapeutic was from BPL, whereas
the Hp2-2-specified product was provided by Benesis Cor-
poration. Phenotype-specified Hb:Hp complexes were sepa-
rated from excessive (nonbound) Hb by gel chromatography
on HiLoad 26/60 Superdex 200 chromatography column (GE
Healthcare Lifesciences). Throughout the study quantities of
Hb and Hb:Hp complexes are given as heme molarity mea-
sured by spectrophotometry. For the in vivo experiments
where (Hb free) Hp therapeutics are administered, Hp
quantities are indicated by protein mass (mg). The reason for
this is that the Hb binding capacity of Hp is proportional to
the protein mass but not to the molar quantity of the hetero-
geneous Hp2-2 molecules.
SPR measurement
SPR measurements were performed on a Proteon XPR36
Instrument (BioRad). Hp1-1/Hp2-2 was immobilized on a
ProteOn Sensor Chip GLMusing the amino coupling reagents
(BioRad). To deactivate the remaining surface groups in the
activated channels, 1 M ethanolamine-HCl (pH 8.5; BioRad)
was injected. The running buffer used for the association
studies with Hb was 150mM sodium chloride (NaCl), 10mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic, 3mM ethylene-
diaminetetraacetic acid, and 0.005% Tween-20 (pH 7.4).
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In vivo studies in guinea pigs
Male Hartley guinea pigs (Charles Rivers Laboratories)
were acclimated for 1week upon arrival to the Food andDrug
Administration (FDA)/Center for Biologics Evaluation and
Research (CBER) animal care facility. All animals weighed
400–450 g before surgery. Animal protocols were approved
by the FDA/CBER Institutional Animal Care and Use Com-
mittee with all experimental procedures performed in ad-
herence to the National Institutes of Health guidelines on the
use of experimental animals. Surgical preparation was per-
formed as previously described (8). Following a 24-h recovery
period, basal blood pressure was collected over 30min via a
right carotid artery catheter connected to Gould P23 XL
pressure transducer (Gould Instrument Systems Inc.). Arterial
blood pressure was recorded continuously at 100Hz using an
MP100A-CE data acquisition system (Biopac Systems, Inc.).
Four groups were evaluated at the 180mg dose: (I) non-
treated, (II) Hb alone (180mg), (III) Hb (180mg) +Hp1-1
(180mg), and (IV) Hb (180mg) +Hp2-2 (180) (group size
n = 5). For Group I animals received 3ml 0.9% NaCl (3ml/
min). Group II animals received 180mg Hb infused over
3min. For groups III and IV, Hb (180mg) was infused over
3min (1ml/min) to establish a blood pressure response. The
Hb dose was tailored to reach a peak plasma concentration of
500–600 lM. Our previous experience showed that this
treatment evokes strong and reproducible blood pressure
responses and iron deposition in the kidneys (9). Ten minutes
after the start of Hb administration, 180mg of Hp1-1 or 2-2
was infused over 3min (1ml/min). Blood pressure parame-
ters were analyzed off-line using AcqKnowledge software
(Biopac Systems, Inc.). At 30 h after the initial infusion of Hb
or 0.9% NaCl, animals were humanely euthanized with a
100mg/kg solution of Euthasol administered intra-perito-
neal. Animals were immediately perfused of blood via the
arterial catheter with 60ml cold saline, kidneys were excised
and fixed in 10% formalin or frozen at - 80C.
Plasma Hb measurements
Concentrations of ferrous (Fe2+ ) Hb (oxy/deoxy), ferric
(Fe3+ ) Hb, and hemichromes were determined using a multi-
component analysis based on the extinction coefficients for
eachHb species. Hp-bound and unbound fractions of Hbwere
determined by SEC–high-performance liquid chromatography
(SEC-HPLC) using aWaters 600 controller, aWaters 600 pump,
and a Waters 2499 photodiode array detector (Waters, Corp.).
Plasma samples were separated on BioSep-SEC-S3000
(600· 7.5mm) column (Phenomenex) with 0.1 M potassium
phosphate as the mobile phase. All samples were monitored at
k= 280nm and k= 405nm in dual-wavelength mode. Hb-
bound and unbound in plasma was determined by dividing
the Hb peak area and the Hb:Hp peak area by additive areas
under the Hb:Hb chromatographic peak (15min elution Hp2-
2:Hb and 17min elution Hp1-1:Hb) and the Hb chromato-
graphic peak (20min elution) measured at k= 405nm.
Pharmacokinetic analysis
Four groups were evaluated at 60mg Hb exposure: (I)
nontreated, (II) Hb alone (60mg), (III) Hb (60mg) +Hp1-1
(60mg), and (IV) Hb (60mg) +Hp2-2 (60) (group size n= 3–5).
Another four groups were evaluated at 180mg Hb exposure:
(I) nontreated, (II) Hb alone (180mg), (III) Hb (180mg) +
Hp1-1 (180mg), and (IV) Hb (180mg) +Hp2-2 (180) (group
size n= 5). Plasma concentration versus time data were
evaluated for bound and unbound Hb parameters deter-
mined using noncompartmental pharmacokinetic methods.
WinNonlin version 5.2.1 (Pharsight Corp.) were used to cal-
culate PK parameter estimates. The area under the plasma
concentration–time curve (AUC0-INF) was estimated using the
linear trapezoidal rule to the last measurable concentration
(AUC0-INF last) where Clast is the last measurable plasma con-
centration (30 hours). Extrapolation to infinity (AUCC last-INF)
was calculated by dividing Clast by the negative value of the
terminal slope (k) of the log-linear plasma concentration–time
curve. Thus AUC0-INF is equal to the sum of AUC0-C last and
AUCC last-INF. Additional parameters were calculated as fol-
lows: the plasma clearance (CL)was calculated as the dose (lg
heme) divided by AUC0-INF, the mean residence time (MRT)
was calculated as k - 1, the apparent volume of distribution
(Vdss) was calculated as the product of CL andMRT, and half-
life (t1/2) was calculated as ln(2) divided by k. Bound Hb fol-
lowing the 60mg exposure declined to approximately zero by
30 h post-Hb and Hp1-1 and Hp2-2 exposure. This dose al-
lowed for a pharmacokinetic comparison between the twoHp
variants. In 180mgHb exposure groupHb:Hp persisted in the
plasma at similar concentrations well beyond 30h (*72 h).
Saturated plasma concentrations prohibited pharmacokinetic
assessment in this group. Iron histopathology was performed
as described (9). Pharmacokinetic parameter comparisons
were performed based a nonparametric analyses (Kruskal–
Wallis test followed by a Dunns post-test for group compar-
isons) using GraphPad Prism 5 software.
Endothelial permeability assay
HUVECs (Lonza) were grown to confluence on 0.4 lm
polyester membrane (Costar No. 3460) transwell plates. HU-
VECs were cultured in phenol red free endothelial growth
medium (EBM) (Lonza, Clonetics). After 24 h of incubation
new media (1.5ml) was added to each transwell with 300lM
catalase free Hb, purified Hb:Hp1-1 complex or purified
Hb:Hp2-2 complex. After 6 h of incubation, the medium was
collected from the top and bottom of the transwell and
centrifuged for 10min at 15,000 rpm. The supernatant from
top well (lumen) and the bottom well (ablumen) were
analyzed for Hb concentration and bound and free Hb by
SEC-HPLC as described in the blood collection and Hb mea-
surement section of the Materials and Methods.
In vitro NO consumption assay
Constant nitric oxide (NO) levels were generated in a
closed stirred 2ml glass chamber by decay of the long half-life
NO donor DETANONOate (Enzo Life Sciences). The reaction
was performed with 5mMDETANONOate in argon purged,
essentially anaerobic phosphate buffered saline (PBS) (pH 7.4;
w/o Ca/Mg) at 23C. NO was monitored at a 1/s recording
rate with a Clark-type NO microsensor (Unisense). Hb or
Hb:Hp complexes were injected into the system at a concen-
tration of 62.5 lM (heme equivalent) with a gas-tight Ha-
milton syringe as three consecutive identical boluses at 30 s
intervals. Alternatively, pre- or post-infusion plasma samples
were injected at a fixed volume of 7.5 ll. Data were recorded
using SensorTrace basic software (Unisense). Statistical
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analysis of replicate measurements was performed with
GraphPad Prism Software Version 5.01.
Spectral analyses of Hb H2O2 reactions
A solution containing PBS (pH 7.2; Gibco) enriched with
glucose (20mM) and a total concentration of 12.5 lM heme
equivalent of either Hb, Hb:Hp1-1, or Hb:Hp2-2 was pre-
pared in 1ml spectrophotometer cuvettes and pre-warmed
at 37C. Basic ferrous Hb (Fe2 + ) spectra were measured
using a Cary 60 UV-Vis spectrophotometer (Agilent Tech-
nologies) across 300–700 nm wavelength range, in steps of
2 nm. GOX was subsequently added to a final concentration
of 40mU/L and full spectra were recorded at every minute
over the period of 5 h. In an equivalent parallel setting, bo-
vine catalase was added to the reaction mixture after 12min.
During the entire measurement process, the temperature
was maintained at 37C using a PCB 1500 Water Peltier
System (Varian). Reference spectra of ferrous oxy-Hb (Fe2 + ),
ferric-Hb (Fe3 + ), and ferryl-Hb (Fe4 + ) were recorded at 37C
in PBS (pH 7.2). For each time point, the concentration of
oxy-Hb, ferric-Hb, and ferryl-Hb in the reaction mixtures
were deconvoluted out of the full recorded spectrum by
applying Lawson–Hanson’s Non Negative Least Squares
algorithm of SciPy (www.scipy.org; see Supplementary Fig.
S6 for details of the deconvolution procedure). The decay (k2)
of ferryl (shown in Fig. 7A, B) was modeled according to the
following reaction:
HbþH2O2!k1 FerrylHb!k2 Degen:Hb
With the equation : [Ferryl]¼
[Hb]0  k1
k1 k2  e
 k2t  [Hb]0  k1  e
 k1t
k1 k2
Hb-Hpx heme transfer
met-Hb (Fe3 + ) (10lM in PBS [pH 7.4]) was incubated with
a twofold molar excess of Hpx (Athens Research and Technol-
ogy, Inc). Serial UV-VIS spectra were recorded using a Cary 60
UV-VIS Spectrophotometer (Agilent Technologies) in order to
follow the transition of met-Hb to heme-Hpx over time. For
each time-point, the concentrations ofmet-Hb andheme-Hpx in
the reaction mixtures were deconvoluted out of the full spec-
trum by applying Lawson–Hanson’s Non Negative Least
Squares algorithmof SciPy (www.scipy.org). Rates of heme loss
from met-Hb were calculated by fitting the following model to
the data by nonlinear regression using R (www.r-project.org):
[Hb]¼ [Hb]0
2
 (e k1tþ e k2 t)
The two rates (fast and slow) may represent the differing
stability of a-globin heme and b-globin heme, respectively (13).
LDL peroxidation
Human plasma-derived LDL was donated by Dr. L.
Rohrer, Institute of Clinical Chemistry, University Hospital of
Zurich. LDL (0.1 g/L) oxidation was measured in an airtight
micro-respiration chamber (Unisense) in PBS (pH 7.45) at
37C. The LDL solution was referenced as 100% of available
oxygen. After a period of signal stabilization, Hb or Hb:Hp
complexes (100% ferric) were injected at a final concentration
of 5lM. Oxygen consumption during Hb-driven LDL
peroxidation was measured by an oxygen sensor (OX-MR;
Unisense) connected to a picoampere-meter PA2000 and an
OXY-Meter ADC216USB (Unisense). Data were recorded
using the Unisense SensorTrace BASIC Software version 3.0.2.
Before each experiment, the oxygen sensor was calibrated in
an anoxic solution containing ascorbic acid and sodium
hydroxide, both to a final concentration of 0.1 M.
Endothelial ECIS and viability measurement
Humanumbilical vein endothelial cells (Lonza)were cultured
in phenol red free EBM (Lonza, Clonetics) and seeded on col-
lagen-coated ECIS Cultureware Disposable Electrode Arrays
8W10E+72h before commencing the experiments. Electrical
impedance was recorded in the multiple frequency mode in a
ECIS ZTheta System (Applied BioPhysics) and analyzed with
ECIS software (data given in the figures correspond to the
4000Hz recordings). Relative endothelial ATP concentrations
weremeasuredwith a luminescent cell viability assay (CellTiter-
Glo Luminescent Cell Viability Assay; Promega).
Mass spectrometry measurements of relative Hb
binding capacity
Phenotype-specified Hb-saturated and HPLC purified
Hb:Hp complexes were quantified by UV-VIS spectropho-
tometry and equal amounts of heme-equivalent complexwere
used for the isotope labeling procedure. Mass differential
Tags for Relative and Absolute Quantification (mTRAQ)-4
and mTRAQ-0 label was applied to Hb:Hp1-1 and Hb:Hp2-2
complex, respectively. Next, 100 lg heme equivalent of each
complex was digested with sequencing grade trypsin (Prome-
ga) and labeledwith the respective tag according to themTRAQ
reagents protocol (Applied Biosystems). Samples were desalted
with ZipTip (Millipore). Mass spectrometry analysis was per-
formed on an LTQ-Orbitrap-Velos (Thermo) coupled to an
Eksigent nanoHPLC. Peptides were identified by information-
dependent acquisition of fragmentation spectra of multiple-
charged peptides. Up to 20 data-dependent MS/MS spectra
were acquired in the linear ion trap for each full scan spec-
trum acquired in the Orbitrap. Collision-induced dissociation
with collision energy 35 was chosen for fragmentation. Proteins
were identified and quantified using MaxQuant Software
(www.maxquant.org) Version 1.3.0.5 and Hb and Hp peptide
quantificationwas performed by integrating theMS1 ion signal
intensity over time using XCalibur Software (Thermo).
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Abbreviations Used
AUC¼ area under the curve
CBER¼Center for Biologics Evaluation and Research
Cl¼plasma clearance
Clast¼ last measurable plasma concentration
EBM¼ endothelial growth medium
ECIS¼ electric cell impedance substrate
FDA¼ Food and Drug Administration
GOX¼ glucose oxidase
H2O2¼hydrogen peroxide
Hb¼hemoglobin
HO-1¼heme-oxygenase 1
Hp¼haptoglobin
HPLC¼high-performance liquid chromatography
Hpx¼hemopexin
HUVECs¼human umbilical vein endothelial cells
k¼ terminal slope (k) of the log-linear plasma
concentration-time curve
LC-MS/MS¼ liquid chromatography mass spectrometry
LDL¼ low-density lipoprotein
MAP¼mean arterial blood pressure
MRT¼mean residence time
NaCl¼ sodium chloride
NO¼nitric oxide
oxLDL¼ oxidized LDL
PBS¼phosphate buffered saline
SDS-PAGE¼ sodium dodecyl sulfate polyacrylamide
gel electrophoresis
SEC¼ size-exclusion chromatography
SPR¼ surface plasmon resonance
t1=2¼ terminal elimination half-life
UV-VIS¼UV-VIS spectrophotometry
Vdss¼ apparent volume of distribution
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